The stock of Novo Nordisk ADR (NYSE:NVO) last traded at $87.37, down -0.32% from the previous session.
NVO stock price is now -18.18% away from the 50-day moving average and -30.29% away from the 200-day moving average. The market capitalization of the company currently stands at $291.68B.
With the price target of $156, Goldman recently initiated with Buy rating for Novo Nordisk ADR (NYSE: NVO). On April 12, 2024, BMO Capital Markets recently initiated its ‘Outperform’ rating on the stock quoting a target price of $163, while ‘Morgan Stanley’ rates the stock as ‘Overweight’
A total of 0.03% of the company’s stock is owned by insiders.
During the past 12 months, Novo Nordisk ADR has had a low of $81.50 and a high of $148.15. As of last week, the company has a debt-to-equity ratio of 0.47, a current ratio of 0.94, and a quick ratio of 0.75. According to the stock market information, the enterprise value for the company is $371088457728, which is based on a 28.33 price-to-earnings ratio, a 2.58 price-to-earnings-growth ratio, and a beta of 0.42. The fifty day moving average price for NVO is $106.7862 and a two-hundred day moving average price translates $125.3391 for the stock.
The latest earnings results from Novo Nordisk ADR (NYSE: NVO) was released for 2024-09-30. The net profit margin was 35.03% and return on equity was 88.20% for NVO. The company reported revenue of $10.51 billion for the quarter, compared to $8.57 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 22.58 percent.
